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Screening for genomic rearrangements is a fundamental task in the genetic diagnosis of many inherited
disorders including cancer-predisposing syndromes. Several methods were developed for analysis of structural
genomic abnormalities, some are targeted to the analysis of one or few specific loci, others are designed to
scan the whole genome. Locus-specific methods are used when the candidate loci responsible for the specific
pathological condition are known. Whole-genome methods are used to discover loci bearing structural
abnormalities when the disease-associated locus is unknown. Three main approaches have been employed for
the analysis of locus-specific structural changes. The first two are based on probe hybridization and include
cytogenetics and DNA blotting. The third approach is based on PCR amplification and includes microsatellite or
single nucleotide polymorphism (SNP) genotyping, relative allele quantitation, real-time quantitative PCR, long
PCR and multiplex PCR-based methods such as multiplex ligation-dependent probe amplification and the
recently developed nonfluorescent multiplex PCR coupled to high-performance liquid chromatography analysis.
Whole-genome methods include cytogenetic methods, array-comparative genomic hybridization, SNP array
and other sequence-based methods. The goal of the present review is to provide an overview of the main
features and advantages and limitations of methods for the screening of structural genomic abnormalities
relevant to oncological research.
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introduction
Extended genomic rearrangements are recognized to play
a pathogenic role in an increasing number of human genetic
diseases and are relatively frequent, representing 7.4% of
reported mutations in the January 2007 release of the Human
Gene Mutation Database [1]. Therefore, screening for
genomic rearrangements is a fundamental task in the genetic
diagnosis of many inherited disorders including cancer-
predisposing syndromes. In fact, rearrangements were reported
to play a relevant role in familial cancer predisposition
syndromes, such as hereditary nonpolyposis colorectal cancer
[2], familial adenomatous polyposis coli and familial breast and
ovarian cancers [3]. The relevance of genomic rearrangement
analysis in oncological research is not limited to germline
alterations since somatic alterations of genomic structure
play a key role in the pathogenesis of cancer. The identification
of somatic rearrangements in tumors is extremely important as
it may provide novel markers for prediction of response to
therapy and for prognosis and may uncover new potential
therapeutic targets. Thus, the development of routine
methods for the identification of genomic rearrangements is
highly needed. A growing number of technologies are
becoming available for this purpose. In this review we
provide a summary of the main features, advantages and
limitations of methods for the screening of structural
genomic abnormalities that are employed in oncological
research. Among the wide range of methods developed
for the analysis of structural genomic abnormalities, some
are targeted to the analysis of one or few specific loci, and
others are designed to scan the whole genome. Locus-specific
methods are used when the candidate loci responsible for
the specific pathological condition are known. The advantage
of locus-specific methods is their cost-effectiveness and the
relatively high resolution achieved. Alternatively, whole-
genome methods are used to discover loci bearing structural
abnormalities when the disease-associated locus is
unknown. These methods are currently expensive and the
resolution achieved is generally lower, but both disadvantages
are likely to be overcome by evolving technological
developments.
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locus-specific methods
Three main approaches have been employed for the analysis of locus-
specific structural changes, the first two are based on probe hybridization
and include cytogenetics and DNA blotting (Southern or dot blotting), and
the third approach is based on PCR amplification. Because of the broadest
availability of PCR, most of the methods developed are based on this
approach.
fluorescent in situ hybridization
This methods is based on the hybridization of fluorescent probes to
metaphase or interphase nuclei followed by analysis with a fluorescence
microscope. FISH detects cancer-related defects in genomic structure
involving altered copy number (deletions and duplications) or without net
copy number changes (translocations and inversions) [4, 5]. The principle
of FISH can be applied not only for locus-specific analysis but also for
whole-genome analysis using multicolor probes (see below). The resolution
of the method ranges from entire chromosomes to single loci and can be
narrowed down to a few kilobases using fiber-FISH. The preparation of
fiber-FISH is, however, not routinely available, making the resolution one
of the limitations of this method. Moreover, FISH is relatively labor
intensive compared with other methods.
Southern and dot blotting
Southern and dot blotting can be used to detect copy number changes
(deletions and duplications) as compared with an internal standard. In
addition, Southern blotting may reveal novel restriction fragments created
by the rearrangements (e.g. junction fragments), which may indicate the
presence of structural changes not associated to copy number changes
(translocations or inversion). In this respect, polymorphisms may hamper
the interpretation of the results of Southern blotting when a single
restriction enzyme is employed. Carrying out independent experiments
with different enzymes can overcome this problem. In general, these
methods are considered of limited value as routine applications in cancer
genetics, since they are laborious and time consuming, require large
amounts of high-molecular weight DNA and their interpretation may
be hampered by false-negative results [6].
PCR-based methods
Several PCR-based protocols were developed because these techniques are
more suited than FISH and Southern blot for routine applications.
microsatellite or single nucleotide polymorphism genotyping and relative
quantitation of alleles. Loss of a polymorphic allele marker in tumors (loss
of heterozygosity) has been commonly employed to detect somatic
deletions in tumors. Polymorphic microsatellite loci and/or single
nucleotide polymorphism (SNP) markers have been employed for this
purpose. Aneuploidies including supernumerary chromosomes [7] were
investigated using quantitative PCR of short tandem repeats. SNPs are,
however, more suited to achieve relative quantitation of alleles either by
primer extension experiments [8, 9] or by pyrosequencing [10] and can
be employed to detect changes in allele copy number (deletions and
duplications), but not balanced rearrangements (translocations or
inversion). All these methods are relatively simple, cost-effective and with
the exception of pyrosequencing, can be implemented using standard
equipment available in all molecular biology laboratories. They require
heterozygous polymorphic markers in the genomic region of interest,
which is not generally a limitation because the human genome contains
millions of polymorphic SNP markers and a relatively large number of
microsatellites.
real-time quantitative PCR. Real-time PCR is a practical and accurate
way to achieve quantitation of a specific genomic target and can be
applied to the determination of gene copy number [11]. A number of
different applications using probes or intercalating dyes are available but
the use of locus-specific probes appears more robust as it avoids nonspecific
signals that may hamper the interpretation of results. The accuracy of the
quantitation, the short hands-on time required for each determination
and the closed system that helps to reduce contaminations are among
the advantages of real-time PCR. The main disadvantages are the high
cost of probes and limitations in the number of multiplex determinations in
a single tube. Moreover, the analysis of duplications may be problematic
since the signal increment contributed by one extra copy of a given gene
would result in a maximum of 3:2 differences as compared with wild type.
long PCR. The method relies on the use of a mixture of two thermostable
DNA polymerases, a proofreading and a nonproofreading [12]. This
combination allows longer primer extension and larger size of
amplicons to be amplified from good-quality genomic DNA (gDNA)
(up to 30-kb fragments). Long-range PCR has been used to identify large
deletions/duplications and chromosome breakpoints in several disorders
because it allows unequivocal confirmation of rearrangements and
provides a PCR-based diagnostic tool to search for the specific germline
mutation in at-risk family members [6]. However, breakpoint
characterization can be very time consuming and it is particularly
challenging in case of rearrangements involving fragments too large to be
amplified or encompassing the first or the last exon of a gene [6, 13–17].
Therefore, long-range PCR is not easily implemented in a routine
mutation scanning.
multiplex PCR-based methods
These methods are designed to screen for copy number changes by
comparative quantitation of simultaneously amplified DNA fragments
representative of the multiple loci to be analyzed (Figure 1). They are
among the best methods available for this purpose. Their limitation is
that balanced rearrangements are not detected, but this is not a major
limitation because copy number changes appear to be more frequently
implicated in the pathogenesis of cancer than balanced rearrangements.
Many methods were developed to detect copy number changes, including
multiplex ligation-dependent probe amplification (MLPA), multiplex
amplifiable probe hybridization (MAPH), quantitative multiplex PCR
of short fluorescent fragments (QMPSF) and nonfluorescent multiplex
PCR coupled to high-performance liquid chromatography (NFMP-HPLC)
analysis. These semiquantitative PCR protocols rely either on capillary
electrophoresis analysis of fluorescently labelled multiplex PCR (MAPH,
MLPA and QMPSF) (Figure 1, panels A, B and C) [2, 18, 19] or, more
recently, on the analysis of nonfluorescent multiplex PCR coupled to
HPLC (NFMP-HPLC) analysis (Figure 1, panel E) [17]. A caveat of these
methods is the possibility that nucleotide mismatches at the primer-binding
site may interfere with primer hybridization, generating a false
indication of exon deletion [20]. Therefore, for diagnostic purposes, the
independent confirmation of the analyses using two semiquantitative
methods or assays (Figure 2) substantially adds to the confidence of results,
especially in cases where a single exon is involved in the rearrangement
[17]. Another factor that should be considered to ensure unambiguous
results in semiquantitative assays is the quantity and quality of gDNA
templates [2, 6, 17]. In particular, low-quality gDNA templates may
generate anomalous results that are easily recognized because control
peaks are also affected and patterns are not reproducible in replicated
experiments.
multiplex ligation-dependent probe. This assay (Figure 1, panel A) is based
on hybridization of a set of probes (representing the loci of interest) to
gDNA in solution followed by ligation of bound probes. Ligated
products are amplified using fluorescent primers and PCR products are
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Figure 1. Multiplex PCR-based methods. Four methods are outlined in the panels (see text for details): (A) multiplex ligation-dependent probe
amplification (MLPA), (B) multiplex amplifiable probe hybridization (MAPH), (C) quantitative multiplex PCR of short fluorescent fragments (QMPSF)
and (D) nonfluorescent multiplex PCR coupled to high-performance liquid chromatography (NFMP-HPLC) analysis.
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analyzed by capillary electrophoresis [21]. This method has the
advantage of being available as a commercial kit and requires minimal
hands-on time to be completed [19, 22]. In this regard, MLPA might be
considered as an early step in molecular diagnosis for gene dosage
measurements. Up to 40 probe sets have been successfully multiplexed
and MLPA kits have been developed for many genes of interest for oncology
research [23–25]. The costs and hands-on time required for each analysis
are potential limitations of this fluorescent assay.
multiplex amplifiable probe hybridization. This method (Figure 1, panel B)
is based on hybridization of a set of probes to gDNA fixed on a solid
support, followed by washing of the unbound probes. Bound probes are
PCR amplified with fluorescent primers and analyzed by capillary
electrophoresis [21]. These probes are generated by cloning and are all
flanked by the same vector sequences, allowing the use of universal PCR
primers. This design simplifies the simultaneous amplification of multiple
targets in a single PCR and reduces the cost for the setting of the
method since only one labelled primer is required. Conversely, the
presence of a solid support for DNA may pose a contamination risk. Thus,
in addition to MLPA limitations, MAPH also requires accurate removal
of unbound probes by a stringent washing step, with increased hands-on
time.
quantitative multiplex PCR of short fluorescent. This assay (Figure 1,
panel C) is based on the simultaneous amplification of short sequences
corresponding to the different segments of the genomic region of interest
using locus-specific labelled primers. QMPSF protocols have been
successfully adapted to the analysis of different genes, which can be
screened using several multiplex PCRs [2, 26–28]. The main disadvantage
of QMPSF is the relevant investment for the initial setup of the method,
because several fluorescent primers are in most cases required for the
analysis of multiple gene fragments [2, 26].
nonfluorescent multiplex PCR coupled to high-performance liquid
chromatography analysis. This method recently developed in our
laboratory is similar to QMPSF, except that multiplex PCRs are
nonfluorescent and are analyzed by HPLC [17]. This assay has several
advantages including the short hands-on time required for each reaction,
the low cost of nonfluorescent multiplex PCRs and HPLC analysis.
Moreover, we have previously reported that it may complement MLPA
to provide a robust and cost-effective strategy for screening and
independent confirmation of putative genomic rearrangements [17]
(Figure 2).
whole-genome methods
cytogenetic methods
These methods are useful for the identification of aneuploidies
gross deletions and duplications. FISH with multicolor probes
(e.g. chromosome painting and spectral karyotyping) helps to
identify chromosomal rearrangements. Among cytogenetic
analyses, comparative genomic hybridization (CGH) is
a method employed to detect somatic alterations in genomic
copy number (gains/losses) in tumor cells [29]. The method is
based on the hybridization of test/proband (e.g. tumor)
and normal DNA (fluorescently labelled with distinct colors) to
normal human metaphase preparations. Quantitative image
analysis of epiflourescence microscopy reveals regional
differences in the fluorescence ratio of proband and control
DNA, reflecting abnormal copy number in specific regions of
proband cell genome. CGH has a low resolution and is not
suited to detect balanced reciprocal translocations
or inversions. More recently, CGH has been adapted to the use
of array-based technology (see Array-CGH section) which
greatly increases resolution of the analysis. In general,
cytogenetic methods are relatively labor intensive and even after
using fluorescent probes, the size of the rearrangements that
can be detected remains a limitation especially when alterations
involve only portions of a gene.
array-based methods. Array-CGH. This technique is
a development of the original cytogenetic CGH, but arrays are
used instead of metaphases to hybridize differentially labelled
test and normal DNA. Array-CGH represents one of the best
methods for genome-wide screening of structural variation
involving copy number changes [30]. Large-insert clones or
long oligonucleotides (60–100 bp) are used to construct arrays.
Oligonucleotides have the advantage to achieve an improved
resolution as compared with long clones (from 50 kb down to
a few kilobases). These methods are excellent for whole-genome
analysis, but their present cost and resolution make them less
useful for the routine diagnosis of limited rearrangements in
specific genes, although this limitation may be overcome in the
near future.
Figure 2. Comparison of results obtained by multiplex ligation-dependent probe amplification (MLPA) and nonfluorescent multiplex PCR coupled to
high-performance liquid chromatography (NFMP-HPLC) analysis. Each panel shows representative examples of tracings obtained in a control individual
(top) and in one hereditary nonpolyposis colorectal cancer (HNPCC) patient (bottom) by MLPA (left) and NFMP-HPLC (right) analyses. Control peaks are
labelled c and arrows indicate the putative deletion of MSH2 exon 3 in this patient.
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SNP array. This sequence-based array approach has the
potential to analyze SNP genotypes on a whole-genome basis.
Similar to what is described for genotyping of single SNPs, they
are a useful tool to study somatic variations in copy number
that generate allelic imbalances (e.g. deletions or amplifications
in tumor versus normal DNA) [31]. In addition to somatic
studies these arrays were also used to screen for germline
variation in gene copy number [32, 33]. Using two independent
SNP array platforms, incompatibility of array-generated data
with Mendelian inheritance was successfully used to screen
hemizygous germline deletions in parent–offspring trios [32,
33]. Moreover, using a bead array-based platform, the detection
of clusters of null genotypes identified homozygous deletions,
while deviations from Hardy–Weinberg equilibrium provided
supporting evidence for the presence of either homozygous or
heterozygous germline deletions [33]. SNP arrays are
a powerful tool for the analysis of structural rearrangements in
oncology, but their cost still limits a wide application of this
technology.
other whole-genome methods
A number of other approaches are being pursued for the
analysis of whole-genome structural variations including paired
sequence analysis and comparative sequence analysis [34, 35].
Some of these methods are very powerful, but their description
is beyond the scope of the present review because their cost and
complexity greatly limits a wide application of this technology.
conclusion
Several studies have emphasized the significant role of large
genomic rearrangements in a wide range of common diseases
and phenotypes including cancer [36]. A major challenge,
however, for the measurement of germline and somatic gene
dosage changes is the availability of high-throughput assays
in mutation-scanning studies. In fact, since many current
detection methods have limitations in resolution, robustness
or costs, their use in a routine diagnostic setting is often an
unpractical option. Therefore, the proportion of structural
genomic abnormalities playing a pathogenic role in cancer is
likely to be underestimated. The recent development of
routine methods designed for oncological research, such as
commercial MLPA kits and NFMP-HPLC, should help to
improve the screening of structural abnormalities, providing
a more accurate estimate of these abnormalities. Also,
the rapid evolution of array-based methods and the trend
to produce lower cost chips holds the promise to widen
their application in a clinical setting, which should improve
our understanding of the role of structural abnormalities in
cancer. The application of whole-genome assays, however,
poses another important question that needs to be addressed
to interpret correctly the results of these studies. According
to our current knowledge, many structural variants do not
appear related to genomic disorders or diseases [37, 38],
while others can influence gene dosage and phenotype,
predisposing to or causing disease [36]. Several studies
are currently underway [39, 40] to analyze structural variation
in apparently normal individuals. The results of these studies
should provide a reference to recognize structural variations
unique to cancer that are likely to play a pathogenic role.
Additional studies will be also necessary to understand
whether structural variation identified in apparently
normal individuals may contribute to polygenic cancer
predisposition.
In conclusion, the study of structural variation in
human genome is an active field of research where
developing technological and scientific advancements have the
potential to provide important contributions to oncological
research.
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